Elliott C. Lasser a retired Physician from the University of California, San Diego has set up his own company to develop and commercialize a new topical agent that he has discovered has the ability to treat allergic diseases.
For the past 45 years Elliott Lasser has been studying the adverse effects of injecting of x-ray contrast media (CM). Elliott has discovered that when applied topically and present in sufficient concentration the contrast medium can inhibit any antibody-antigen reaction and any enzymatic reaction. This discovery led Elliott to believe that this property could be exploited for the treatment of allergic diseases where topical administration is feasible.
After a series of basic studies Elliot and his team conducted a 20 person product vs placebo test in humans; The patients symptoms were then evaluated after treatment. A comparison of mean total results for Hexabrix (test substance) vs saline is Hexabrix 3.4 and Saline 8.5. Promising results were obtained from the trials which included for sneezing (p=0.018) and runny nose (p=0.048) These are the two most bothersome symptoms of nasal allergy.
Further information can be obtained regarding this unique and efficient drug from Elliott Lasser direct. There have been no adverse results thus far and because of the nature of these molecules, Elliott believes there is reason to expect that they will be safer than any comparable drug on the market. This drug is now available for licensing at a very low price.
The company is looking to out-license its lead allergic rhinitis project, preferable to a company that could develop it and market it themselves or sell it to a large pharma company to sell. Alternatively companies are welcomed who may wish to buy the patents outright and exploit the IP which ever way they wanted.
Clients in focus...